Scleroderma Drug Development Summit Boston

Memo

SDD is industry's first networking and discussion forum dedicated to solving translational challenges limiting the development of disease modifying scleroderma therapeutics.



With up to 90% of the estimated 2 million affected by systemic sclerosis worldwide developing some degree of lung scarring – the capability of candidates targeting idiopathic pulmonary fibrosis and other manifestations of interstitial lung disease provides promise for the successful re-direction of anti-fibrotic, anti-inflammatory therapeutics into other aspects of SSc multi-organ manifestation.



Bringing together leading researchers from academia and industry, this timely and important meeting will benchmark candidate successes, comprehensively review what is known about disease aetiology and challenge the limitations of current clinical endpoint guidelines.



Attending this industry driven forum will enable you to:



- More effectively translate from preclinical to clinical development beyond the bleomycin mouse model

- Harness better understanding of disease aetiology to more confidently identify disease modifying scleroderma candidates

- Outline the therapeutic potential of your own fibrosis and inflammatory candidates within systemic sclerosis



Time: 8:20 am to 5:15 pm



Prices:

GOLD: USD 3997.0,

SILVER: USD 3398.0,

BRONZE: USD 2799.0



Speakers: Marek Honczarenko (AbbVie), Jeffrey Siegel (Genentech), Gerald Horan (Celgene), Mark Tepper (Corbus Pharmaceuticals), Nicolas Wisniacki (GlaxoSmithKline)



Venue Details: Hilton Boston Woburn, 2 Forbes Road, Woburn, 01801, United States